RemeGen Co. Ltd. Class H (REGMF) AI Stock Analysis

RemeGen Co. Ltd. Class H

(Other OTC:REGMF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong revenue and profitability inflectionThe sharp TTM revenue increase and exceptionally high profitability demonstrate substantial current commercial traction for the company’s therapies. If these results persist, stronger earnings can support reinvestment in clinical development, commercialization, and the broader proprietary product pipeline over coming quarters.

Negative Factors

Earnings durability remains uncertainThe abrupt shift from losses and cash burn to exceptionally high profitability makes the current earnings base difficult to underwrite as a stable trend. Results may remain lumpy if they depend on product mix, milestones, or other factors that do not repeat consistently.

RemeGen Co. Ltd. Class H (REGMF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $35.89B
Dividend Yield: ―
Average Volume (3M): 601
Price to Earnings (P/E): 7.9
Beta (1Y): 2.95
Revenue Growth: 291.47%
EPS Growth: ―
Country: US
Employees: 3,048
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

RemeGen Co. Ltd. Class H Business Overview & Revenue Model

Company Description

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitaci...

RemeGen Co. Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

REGMF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:9969	65Neutral	HKD 16.81B	12.39	17.47%	―	146.27%	―
HK:2696	65Neutral	HKD 26.75B	26.13	20.41%	―	32.63%	8.74%
HK:9966	52Neutral	HKD 6.06B	-30.61	-10.27%	―	-31.77%	-177.01%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:9926	42Neutral	HKD 76.70B	-66.36	-10.86%	―	42.47%	-15.80%
HK:1877	41Neutral	HKD 30.07B	-69.15	-7.23%	―	35.82%	54.40%

* Healthcare Sector Average

Performance Comparison

REGMF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
REGMF	RemeGen Co. Ltd. Class H	8.30	-3.29	-28.41%
HK:9926	Akeso, Inc.	81.50	-29.70	-26.71%
HK:9966	Alphamab Oncology	6.21	-5.01	-44.61%
HK:9969	InnoCare Pharma Ltd.	11.25	-3.10	-21.60%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	15.26	-10.86	-41.58%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	49.06	-13.74	-21.88%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

RemeGen Co. Ltd. Class H AI Stock Analysis